Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Gillman

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Allergology International : Official Journal of the Japanese Society of Allergology|July 1, 2026
Sustained clinical remission and relapse of severe eosinophilic asthma following long-term mepolizumab treatmentRejoy Sabin Thomas, Dennis Thomas, Vanessa M McDonald, et al.
Allergy|September 23, 2018
The 2016 Melbourne thunderstorm asthma epidemic: Risk factors for severe attacks requiring hospital admissionMark Hew, Joy Lee, Nugroho H Susanto, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 27, 2026
A Real-World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe AsthmaDennis Thomas, Vanessa M McDonald, Gijo Thomas, et al.
The European Respiratory Journal|March 7, 2020
Mepolizumab effectiveness and identification of super-responders in severe asthmaErin S Harvey, David Langton, Constance Katelaris, et al.
Respiratory Medicine|September 5, 2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab RegistryErin S Harvey, Yuto Hamada, Sarah A Hiles, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 5, 2021
Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab RegistryDennis Thomas, Erin S Harvey, Vanessa M McDonald, et al.
The Journal of Allergy and Clinical Immunology|November 14, 2021
Thunderstorm asthma in seasonal allergic rhinitis: The TAISAR studyJo A Douglass, Caroline Lodge, Samantha Chan, et al.
The Lancet. Planetary Health|June 9, 2018
The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factorsFrancis Thien, Paul J Beggs, Danny Csutoros, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Allergology International : Official Journal of the Japanese Society of Allergology|July 1, 2026
Sustained clinical remission and relapse of severe eosinophilic asthma following long-term mepolizumab treatmentRejoy Sabin Thomas, Dennis Thomas, Vanessa M McDonald, et al.
Allergy|September 23, 2018
The 2016 Melbourne thunderstorm asthma epidemic: Risk factors for severe attacks requiring hospital admissionMark Hew, Joy Lee, Nugroho H Susanto, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 27, 2026
A Real-World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe AsthmaDennis Thomas, Vanessa M McDonald, Gijo Thomas, et al.
The European Respiratory Journal|March 7, 2020
Mepolizumab effectiveness and identification of super-responders in severe asthmaErin S Harvey, David Langton, Constance Katelaris, et al.
Respiratory Medicine|September 5, 2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab RegistryErin S Harvey, Yuto Hamada, Sarah A Hiles, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 5, 2021
Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab RegistryDennis Thomas, Erin S Harvey, Vanessa M McDonald, et al.
The Journal of Allergy and Clinical Immunology|November 14, 2021
Thunderstorm asthma in seasonal allergic rhinitis: The TAISAR studyJo A Douglass, Caroline Lodge, Samantha Chan, et al.
The Lancet. Planetary Health|June 9, 2018
The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factorsFrancis Thien, Paul J Beggs, Danny Csutoros, et al.
Pageof 3